



| Application Serial No. | Filing Date | Status  |
|------------------------|-------------|---|
|                        |             | <input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned |

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

3-4-02

Date

Name:

Spencer B. FARR

Residence:

~~5 Gwendolyn Court, Santa Fe, NM 87506~~

Citizenship:

U.S.A.

Post Office Address:

Same as above

5 Gwendolyn Court,  
Santa Fe, NM 87506

SBF

SBF

Date

Name:

Gavin G. PICKETT

Residence:

9601 Avenida de la Luna N.E., Albuquerque, New Mexico 87111

Citizenship:

U.S.A.

Post Office Address:

Same as above

Date

Name:

Robin Eileen NEFT

Residence:

424 Serenity Ct. SE, Albuquerque, NM 87123

Citizenship:

U.S.A.

Post Office Address:

Same as above

Date

Name:

Robert Thomas DUNN, II

Residence:

5383 Kim Road B, Rio Rancho, NM 87124

Citizenship:

U.S.A.

Post Office Address:

Same as above



PATENT  
Docket No. 400742000200

# DECLARATION FOR UTILITY/DESIGN PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, WE HEREBY DECLARE THAT:

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: CANINE TOXICITY GENES, the specification of which is attached hereto unless the following box is checked:

☒ was filed on July 23, 2001 as United States Application Serial No. 09/911,904.

WE HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

| Application No. | Country | Date of Filing<br>(day/month/year) | Priority Claimed?  |
|-----------------|---------|------------------------------------|--|
|                 |         |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

| Application Serial No. | Filing Date   |
|------------------------|---------------|
| 60/220,057             | July 21, 2000 |

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, we acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

|                        |             |   |
|------------------------|-------------|---|
| Application Serial No. | Filing Date | Status  |
|                        |             | <input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned |

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

\_\_\_\_\_  
 Date Name: Spencer B FARR  
 Residence: 5 Guendolyn Court, Santa Fe, NM 87501  
 Citizenship: U S.A.  
 Post Office Address: Same as above

2/25/02 \_\_\_\_\_  
 Date Name: *Gavin G. Pickett*  
 Residence: Gavin G. PICKETT  
 9601 Avenida de la luna N E , Albuquerque, New Mexico 87111  
 Citizenship: U.S.A.  
 Post Office Address: Same as above

\_\_\_\_\_  
 Date Name: Robin Eileen NEFT  
 Residence: 424 Serenity Ct. SE, Albuquerque, NM 87123  
 Citizenship: U.S.A.  
 Post Office Address: Same as above

\_\_\_\_\_  
 Date Name: Robert Thomas DUNN, II  
 Residence: 5383 Kim Road B, Rio Rancho, NM 87124  
 Citizenship: U S.A.  
 Post Office Address: Same as above



PATENT  
Docket No. 400742000200

### DECLARATION FOR UTILITY/DESIGN PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, WE HEREBY DECLARE THAT:

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: CANINE TOXICITY GENES, the specification of which is attached hereto unless the following box is checked:

☒ was filed on July 23, 2001 as United States Application Serial No. 09/911,904.

WE HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

| Application No. | Country | Date of Filing<br>(day/month/year) | Priority Claimed?  |
|-----------------|---------|------------------------------------|--|
|                 |         |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

| Application Serial No. | Filing Date   |
|------------------------|---------------|
| 60/220,057             | July 21, 2000 |

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, we acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

| Application Serial No. | Filing Date | Status  |
|------------------------|-------------|---|
|                        |             | <input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned |


We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date \_\_\_\_\_ Name Spencer B FARR  
 Residence 5 Guendolyn Court, Santa Fe, NM 87501  
 Citizenship U.S.A.  
 Post Office Address: Same as above

Date \_\_\_\_\_ Name: Gavin G. PICKETT  
 Residence 9601 Avenida de la luna N.E., Albuquerque, New Mexico 87111  
 Citizenship U.S.A.  
 Post Office Address: Same as above

2/18/02 Robin Eileen Neft  
 Date \_\_\_\_\_ Name Robin Eileen NEFT  
 Residence 424 Serenity Ct. SE, Albuquerque, NM 87123  
 Citizenship U.S.A.  
 Post Office Address: Same as above

Date \_\_\_\_\_ Name: Robert Thomas DUNN, II  
 Residence 5383 Kim Road B, Rio Rancho, NM 87124  
 Citizenship U.S.A.  
 Post Office Address: Same as above



*Cynthia A. Padilla*



PATENT  
Docket No. 400742000200

### DECLARATION FOR UTILITY/DESIGN PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, WE HEREBY DECLARE THAT:

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: CANINE TOXICITY GENES, the specification of which is attached hereto unless the following box is checked:

☒ was filed on July 23, 2001 as United States Application Serial No. 09/911,904.

WE HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

| Application No. | Country | Date of Filing<br>(day/month/year) | Priority Claimed?  |
|-----------------|---------|------------------------------------|--|
|                 |         |                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

| Application Serial No. | Filing Date   |
|------------------------|---------------|
| 60/220,057             | July 21, 2000 |

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, we acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

|                        |             |   |
|------------------------|-------------|---|
| Application Serial No. | Filing Date | Status  |
|                        |             | <input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned |

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Name: Spencer B FARR  
Residence: 5 Guendolyn Court, Santa Fe, NM 87501  
Citizenship: U.S.A.  
Post Office Address: Same as above


\_\_\_\_\_  
Date

\_\_\_\_\_  
Name: Gavin G. PICKETT  
Residence: 9601 Avenida de la luna N.E , Albuquerque, New Mexico 87111  
Citizenship: U.S.A.  
Post Office Address: Same as above

\_\_\_\_\_  
Date

\_\_\_\_\_  
Name: Robin Eileen NEFT  
Residence: 424 Serenity Ct. SE, Albuquerque, NM 87123  
Citizenship: U.S.A.  
Post Office Address: Same as above

3/26/02  
Date

  
\_\_\_\_\_  
Name: Robert Thomas DUNN, II  
Residence: 5383 Kim Road B, Rio Rancho, NM 87124  
Citizenship: U.S.A.  
Post Office Address: Same as above



PATENT

Docket No. 400742000200



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Spencer B. FARR et al.

Serial No.: 09/911,904

Filing Date: July 23, 2001

For: CANINE TOXICITY GENES

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

**PROSECUTION BY ASSIGNEE AND POWER OF ATTORNEY  
UNDER 37 C.F.R. § 3.71**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Phase-1 Molecular Toxicology, Inc., the assignee of the entire right, title and interest in this patent application, under 37 C.F.R. § 3.71 hereby appoints:

Lisa A. Amii (Reg No. 48,199)  
Mehran Arjomand (Reg No. 48,231)  
Sanjay S. Bagade (Reg No. 42,280)  
Shantanu Basu (Reg No. 43,318)  
Vincent J. Belusko (Reg No. 30,820)  
Kimberly A. Bolin (Reg No. 44,546)  
Tyler S. Brown (Reg No. 36,465)  
A. Randall Camacho (Reg No. 46,595)  
Robert K. Cerpa (Reg No. 39,933)  
Alex Chartove (Reg No. 31,942)  
Thomas E. Ciotti (Reg No. 21,013)  
Matthew M. D'Amore (Reg No. 42,457)  
Peter Davis (Reg No. 36,119)  
Karen B. Dow (Reg No. 29,684)  
Carolyn A. Favorito (Reg No. 39,183)  
Hector Gallegos (Reg No. 40,614)  
Debra J. Glaister (Reg No. 33,888)  
Bruce D. Grant (Reg No. 47,608)  
Douglas G. Hodder (Reg No. 41,840)

Randolph Ted Apple (Reg No. 36,429)  
Laurie A. Axford (Reg No. 35,053)  
Erwin J. Basinski (Reg No. 34,773)  
Richard R. Batt (Reg No. 43,485)  
Jonathan Bockman (Reg No. 45,640)  
Barry E. Bretschneider (Reg No. 28,055)  
Nicholas Buffinger (Reg No. 39,124)  
Mark R. Carter (Reg No. 39,131)  
Peng Chen (Reg No. 43,543)  
Thomas Chuang (Reg No. 44,616)  
Cara M. Coburn (Reg No. 46,631)  
Raj S. Davé (Reg No. 42,465)  
David Devernoe (Reg No. 29,684)  
Stephen C. Durant (Reg No. 31,506)  
David L. Fehrman (Reg No. 28,600)  
Thomas George (Reg No. 45,740)  
Kenneth R. Glick (Reg No. 28,612)  
John U. Han (Reg No. 45,565)  
Alan S. Hodes (Reg No. 38,185)

Charles D. Holland (Reg No. 35,196)  
 Peter Hsieh (Reg No. 44,780)  
 Wayne Jaeschke, Jr. (Reg No. 38,503)  
 Parisa Jorjani (Reg No. 46,813)  
 Richard C. Kim (Reg No. 40,046)  
 Lawrence B. Kong (Reg No. P49,043)  
 Glenn Kubota (Reg No. 44,197)  
 Michael J. Mauriel (Reg No. 44,226)  
 Philip A. Morin (Reg No. P-45,926)  
 Mabel Ng (Reg No. P48,922)  
 Catherine M. Polizzi (Reg No. 40,130)  
 Robert E. Scheid (Reg No. 42,126)  
 Terri Shieh-Newton (Reg No. 47,081)  
 Kevin R. Spivak (Reg No. 43,148)  
 Thomas L. Treffert (Reg No. P48,279)  
 Michael R. Ward (Reg No. 38,651)  
 Todd W. Wight (Reg No. 45,218)  
 Frank Wu (Reg No. 41,386)  
 Peter J. Yim (Reg No. 44,417)  
 Karen R. Zachow (Reg No. 46,332)

Kelvan P. Howard (Reg No. P48,999)  
 Jill A. Jacobson (Reg No. 40,030)  
 Madeline I. Johnston (Reg No. 36,174)  
 Ararat Kapouytian (Reg No. 40,044)  
 Cameron A. King (Reg No. 41,897)  
 Kawai Lau (Reg No. 44,461)  
 Rimas T. Lukas (Reg No. 46,451)  
 Gladys H. Monroy (Reg No. 32,430)  
 Kate H. Murashige  
 Martin M. Noonan (Reg No. 44,264)  
 Phillip Reilly (Reg No. 41,415)  
 Debra A. Shetka (Reg No. 33,309)  
 Rebecca Shortle (Reg No. 47,083)  
 Stanley H. Thompson (Reg No. 45,160)  
 Brenda J. Wallach (Reg No. 45,193)  
 E. Thomas Wheelock (Reg No. 28,825)  
 Eric Witt (Reg No. 44,408)  
 David T. Yang (Reg No. 44,415)  
 George C. Yu (Reg No. 44,418)

all of Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018, telephone (650) 813-5600, to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71 provided that if any one of said attorneys or agents ceases being affiliated with the law firm of Morrison & Foerster as partner, employee or of counsel, such attorney's or agent's appointment as attorney or agent and all powers derived therefrom shall terminate on the date such attorney or agent ceases being so affiliated.

Please direct all written communications relative to this application to:


Terri M. Shieh-Newton  
 Morrison & Foerster LLP  
 755 Page Mill Road  
 Palo Alto, California 94304-1018

Please direct all telephone communications to Terri M. Shieh-Newton at (650) 813-5649.

Phase-1 Molecular Toxicology, Inc.  
a Delaware corporation

Dated: 2-28, 2002 

Name: Kenneth P. Redwine  
Title: Corporate Secretary  
Address: 2904 Rodeo Park Drive East  
Santa Fe, NM 87505



PTO/SB/96 (08-00)  
Approved for us through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Applicant/Patent Owner: Spencer B. FARR et al.  
Application No./Patent No.: 09/911,904 Filed/Issue Date: July 23, 2001  
Entitled: CANINE TOXICITY GENES  
Phase-1 Molecular Toxicology, Inc., a \_\_\_\_\_ corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

1. ☒ the assignee of the entire right, title, and interest; or


2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by, percentage) of its ownership interest is \_\_\_\_\_ %

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

Feb 21, 2002  
Date

KENNETH P. REDWINE  
Print Name  
  
Signature  
CORPORATE SECRETARY  
Title

**Burden Hour Statement.** This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.**

pa-645346

**COPY**

Attorney Docket No.: 400742000200

**ASSIGNMENT  
JOINT**

THIS ASSIGNMENT, by Spencer B. FARR, Gavin G. PICKETT, Robin Eileen NEFT, and Robert Thomas DUNN, II (hereinafter referred to as the assignors), residing at ~~5 Guendolyn Court, Santa Fe, NM 87504~~ <sup>58F</sup> 5 Guendolyn Court, Santa Fe, NM 87506, 9601 Avenida de la Luna N.E., Albuquerque, New Mexico 87111, 424 Serenity Ct. SE, Albuquerque, New Mexico, 87123 and 5383 Kim Road B, Rio Rancho, New Mexico, 87124, respectively, witnesseth:

WHEREAS, said assignors have invented certain new and useful improvements in CANINE TOXICITY GENES, set forth in an application for Letters Patent of the United States, bearing Serial No. 09/911,904 and filed on July 23, 2001; and

WHEREAS, Phase-I Molecular Toxicology, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at 2904 Rodeo Park Drive East, Santa Fe, NM 87505 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignors are the sole and lawful owners of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignors will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

Attorney Docket No.: 400742000200

AND said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said assignee, its successors, legal representatives and assigns.

3/4/02  
Date Spencer B. FARR

Date Gavin G. PICKETT

Date Robin Eileen NEFT

Date Robert Thomas DUNN, II

State of NM  
County of SF

Acknowledged before me this 4th day of March  
2002, By Spencer B. Farr.

Karen E. Garcia  
Notary



OFFICIAL SEAL  
KAREN E. GARCIA  
NOTARY PUBLIC-STATE OF NEW MEXICO  
My Comm. Expires 4/29/02

# **COPY**

## **ASSIGNMENT**

### **JOINT**

THIS ASSIGNMENT, by Spencer B. FARR, Gavin G. PICKETT, Robin Eileen NEFT, and Robert Thomas DUNN, II (hereinafter referred to as the assignors), residing at 5 Guendolyn Court, Santa Fe, NM 87501, 9601 Avenida de la luna N.E., Albuquerque, New Mexico 87111, 424 Serenity Ct. SE, Albuquerque, New Mexico, 87123 and 5383 Kim Road B, Rio Rancho, New Mexico, 87124, respectively, witnesseth:

WHEREAS, said assignors have invented certain new and useful improvements in CANINE TOXICITY GENES, set forth in an application for Letters Patent of the United States, bearing Serial No. 09/911,904 and filed on July 23, 2001; and

WHEREAS, Phase-I Molecular Toxicology, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at 2904 Rodeo Park Drive East, Santa Fe, NM 87505 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignors are the sole and lawful owners of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignors will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

Attorney Docket No.: 400742000200

AND said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said assignee, its successors, legal representatives and assigns.

Date  
2/25/02  
Date


Spencer B. FARR  
*Gavin G. Pickett*  
Gavin G. PICKETT

Date

Robin Eileen NEFT

Date

Robert Thomas DUNN, II

*Sharon A. Castillo*  
 OFFICIAL SEAL  
**SHARON A. CASTILLO**  
NOTARY PUBLIC STATE OF NEW MEXICO  
Notary Bond Filed with Secretary of State  
My Commission Expires 01-29-05



**COPY**

Attorney Docket No.: 400742000200

**ASSIGNMENT  
JOINT**

THIS ASSIGNMENT, by Spencer B. FARR, Gavin G. PICKETT, Robin Eileen NEFT, and Robert Thomas DUNN, II (hereinafter referred to as the assignors), residing at 5 Guendolyn Court, Santa Fe, NM 87501, 9601 Avenida de la luna N.E., Albuquerque, New Mexico 87111, 424 Serenity Ct. SE, Albuquerque, New Mexico, 87123 and 5383 Kim Road B, Rio Rancho, New Mexico, 87124, respectively, witnesseth:

WHEREAS, said assignors have invented certain new and useful improvements in CANINE TOXICITY GENES, set forth in an application for Letters Patent of the United States, bearing Serial No. 09/911,904 and filed on July 23, 2001; and

WHEREAS, Phase-I Molecular Toxicology, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at 2904 Rodeo Park Drive East, Santa Fe, NM 87505 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignors are the sole and lawful owners of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignors will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.



**COPY**

Attorney Docket No.: 400742000200

**ASSIGNMENT  
JOINT**

THIS ASSIGNMENT, by Spencer B. FARR, Gavin G. PICKETT, Robin Eileen NEFT, and Robert Thomas DUNN, II (hereinafter referred to as the assignors), residing at 5 Guendolyn Court, Santa Fe, NM 87501, 9601 Avenida de la luna N.E., Albuquerque, New Mexico 87111, 424 Serenity Ct. SE, Albuquerque, New Mexico, 87123 and 5383 Kim Road B, Rio Rancho, New Mexico, 87124, respectively, witnesseth:

WHEREAS, said assignors have invented certain new and useful improvements in CANINE TOXICITY GENES, set forth in an application for Letters Patent of the United States, bearing Serial No. 09/911,904 and filed on July 23, 2001; and

WHEREAS, Phase-I Molecular Toxicology, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at 2904 Rodeo Park Drive East, Santa Fe, NM 87505 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignors are the sole and lawful owners of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignors will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said assignee, its successors, legal representatives and assigns.

Date

Spencer B. FARR

Date

Gavin G. PICKETT

Date


Robin Eileen NEFT

Date

3/26/02

Robert Thomas DUNN, II

SUBSCRIBED AND SWORN TO before me this 26 day of March, 2002



Notary Public

My Commission Expires: 3-27-2004